Bionoid Pharma Inc. Engages Aloba, Awomolo & Partners as External Auditor for 2024 Financial Statements

Rhea-AI Summary

Bionoid Pharma (OTC PINK:BINP) has appointed Aloba, Awomolo & Partners, a PCAOB-registered accounting firm, as its independent external auditor for the fiscal year 2024. This strategic move follows the company's recent application to uplist to the OTCQB Venture Market.

The engagement of the new auditor demonstrates Bionoid's focus on enhancing financial governance and transparency, aimed at providing investors with improved visibility and liquidity. The audit is positioned as a important step in the company's strategy to achieve a more senior market listing.

Positive

• Applied for uplisting to OTCQB Venture Market, potentially increasing stock visibility and liquidity
• Engagement of PCAOB-registered auditor strengthens financial governance

Negative

• Currently trading on OTC Pink, the lowest tier of OTC Markets

NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) today announced it has engaged Aloba, Awomolo & Partners, a PCAOB-registered accounting firm, as its independent external auditor for the fiscal year ended December 31, 2024.

This engagement underscores Bionoid's commitment to robust financial governance and transparency, aligning with its strategic initiatives to enhance market presence and shareholder value.

"We are pleased to welcome Aloba, Awomolo & Partners as our auditors for the 2024 fiscal year," said a spokesperson for Bionoid Pharma Inc. "Their expertise will be instrumental as we advance our financial reporting standards. Following our recent application to uplist to the OTCQB Venture Market, this audit represents a critical step toward achieving a more senior listing and reflects our dedication to providing investors with increased visibility and liquidity."

About Bionoid Pharma Inc.

Bionoid Pharma Inc. is a forward-thinking company focused on leveraging artificial intelligence to unlock new commercial opportunities and improve digital engagement. With a strategic emphasis on growth through acquisitions, Bionoid's five-year roadmap includes acquiring revenue-generating businesses and integrating its proprietary AI Maverick technology to enhance operational efficiency and user experience.

AI Maverick is a versatile, AI-powered platform designed to support a wide range of applications, from intelligent customer interaction tools to dynamic communication and data-driven engagement systems. As Bionoid continues to evolve, the flexibility of the Maverick platform provides a foundation for innovation across multiple sectors. Through these initiatives, the company aims to build long-term value, attract strategic partners, and establish a strong position in the rapidly expanding AI ecosystem.

Stay Connected:

Website: https://bionoidpharma.com
https://aimaverickintel.com/
OTC Markets: BINP
X (formerly Twitter): @BionoidPharminc

For Investor and Media Inquiries:

Wayne Cockburn, CEO
(905) 505-0770
Email: bionoidpharma@gmail.com

SOURCE: Bionoid Pharma, Inc.

View the original press release on ACCESS Newswire

FAQ

What is the significance of BINP engaging Aloba, Awomolo & Partners as auditor?

The engagement of a PCAOB-registered firm strengthens financial governance and is important for BINP's planned uplisting to OTCQB Venture Market.

When will Aloba, Awomolo & Partners audit BINP's financial statements?

They will audit Bionoid Pharma's financial statements for the fiscal year ended December 31, 2024.

What are the potential benefits for BINP shareholders from the OTCQB uplisting plan?

Shareholders may benefit from increased stock visibility and liquidity following the planned uplisting to OTCQB Venture Market.

What market does BINP currently trade on?

BINP currently trades on the OTC Pink market.